KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Short-term Investments (2016 - 2023)

Esperion Therapeutics filings provide 7 years of Short-term Investments readings, the most recent being $17.4 million for Q1 2023.

  • On a quarterly basis, Short-term Investments fell 74.42% to $17.4 million in Q1 2023 year-over-year; TTM through Mar 2023 was $17.4 million, a 74.42% decrease, with the full-year FY2022 number at $42.1 million, down 16.56% from a year prior.
  • Short-term Investments hit $17.4 million in Q1 2023 for Esperion Therapeutics, down from $42.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $68.1 million in Q1 2022 to a low of $2.2 million in Q2 2020.
  • Median Short-term Investments over the past 5 years was $33.3 million (2019), compared with a mean of $35.7 million.
  • Biggest five-year swings in Short-term Investments: plummeted 91.64% in 2020 and later decreased 16.56% in 2022.
  • Esperion Therapeutics' Short-term Investments stood at $34.7 million in 2019, then crashed by 93.52% to $2.2 million in 2020, then skyrocketed by 2144.82% to $50.4 million in 2021, then decreased by 16.56% to $42.1 million in 2022, then plummeted by 58.59% to $17.4 million in 2023.
  • The last three reported values for Short-term Investments were $17.4 million (Q1 2023), $42.1 million (Q4 2022), and $29.9 million (Q3 2022) per Business Quant data.